Skip to Content
Morningstar

Sage Therapeutics Inc SAGE

Morningstar Rating
Unlock
Stock XNAS Rating as of
$13.39 +0.36 (2.76%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
SAGE is trading at a 56% discount.
Price
$12.98
Fair Value
$76.79
Uncertainty
Extreme
1-Star Price
$774.42
5-Star Price
$7.42
Economic Moat
Kfmt
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SAGE is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$13.03
Day Range
$13.04–13.58
52-Week Range
$11.00–59.98
Bid/Ask
$13.38 / $13.40
Market Cap
$806.03 Mil
Volume/Avg
407,576 / 1.0 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
9.02
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
487
Website
https://www.sagerx.com

Comparables

Valuation

View More
Metric
SAGE
PLRX
DICE
Price/Earnings (Normalized)
 ———
Price/Book Value
 0.981.634.38
Price/Sales
 9.02477.92—
Price/Cash Flow
 ———
Price/Earnings
SAGE
PLRX
DICE

Financial Strength

Metric
SAGE
PLRX
DICE
Quick Ratio
 10.1117.4325.69
Current Ratio
 10.5117.7225.88
Interest Coverage
 —−145.34−214.24
Quick Ratio
SAGE
PLRX
DICE

Profitability

Metric
SAGE
PLRX
DICE
Return on Assets (Normalized)
 −39.60%−22.68%−18.86%
Return on Equity (Normalized)
 −43.61%−24.50%−20.04%
Return on Invested Capital (Normalized)
 −47.08%−28.46%−22.67%
Return on Assets
SAGE
PLRX
DICE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNrpctzblbbMklv$550.4 Bil
VRTX
Vertex Pharmaceuticals IncMbwhvxygsHrzjlj$101.7 Bil
REGN
Regeneron Pharmaceuticals IncKhfkqtbvGhnxm$98.1 Bil
MRNA
Moderna IncPtkpjvkwQqrlw$39.1 Bil
ARGX
argenx SE ADRRvrcjbkbFbd$21.7 Bil
BNTX
BioNTech SE ADRHtdhrhvyRfml$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncGqlpskwbThgdn$18.4 Bil
BMRN
Biomarin Pharmaceutical IncMwwcnygqRggtyg$17.1 Bil
RPRX
Royalty Pharma PLC Class AFbtvztbrpKncfmf$12.5 Bil
INCY
Incyte CorpKswyxfyDdmjypn$11.9 Bil

Sponsor Center